Location via proxy:   [ UP ]  
[Report a bug]   [Manage cookies]                
Scribd Logo
Upload

Welcome to Scribd!

  • 11 views

    Marksans Pharma

    Uploaded by

    Kashish

    Copyright:

    © All Rights Reserved
    Download as PDF, TXT or read online from Scribd

    Marksans Pharma

    Uploaded by

    Kashish
    11 views6 pages

    Original Title

    MARKSANS PHARMA

    Copyright

    © © All Rights Reserved

    Available Formats

    PDF, TXT or read online from Scribd

    Did you find this document useful?

    Is this content inappropriate?

    Copyright:

    © All Rights Reserved
    Download as PDF, TXT or read online from Scribd
    Download as pdf or txt
    11 views6 pages

    Marksans Pharma

    Uploaded by

    Kashish

    Copyright:

    © All Rights Reserved
    Download as PDF, TXT or read online from Scribd
    Download as pdf or txt
    of 6

    MARKSANS PHARMA

    Marksans Pharma Limited is a public limited company incorporated in the year April 16th, 1982. The
    Company is primarily engaged in the business of research, manufacture, marketing and sale of
    pharmaceutical formulation..In 2001 Marksans was incorporated as a wholly owned subsidiary of Glenmark
    Pharmaceuticals Ltd the company has progressively strengthened its position, establishing a notable presence in the
    global pharmaceutical arena.

    Marksans Pharma is at the forefront of the pharmaceutical industry, distinguished by a customer-centric approach.
    Specializing in Over-the-Counter (OTC) and prescription drugs(Pain Management, Cough and Cold, Digestives, CVS,
    CNS Oncology, Antidiabetic, and Antibiotics, among others.), they have cultivated a strong presence in highly
    regulated markets.

    Leveraging robust Research and Development (R&D) capabilities and advanced manufacturing facilities both
    domestically and internationally, they are among the top five Indian Companies in the United Kingdom. Their
    strategic emphasis on optimizing supply chain efficiencies has facilitated substantial business expansion across key
    global markets. Their high-quality and expansive portfolio has led to a growing foothold in the USA as well.

    Rigorous Quality Control (QC) and Quality Assurance (QA) processes have positioned them as a niche player in the
    pharmaceutical ecosystem.

    COMPANY AT GLANCE:

    •Marksans was incorporated as a wholly owned subsidiary of


    2001 Glenmark Pharmaceuticals Ltd.

    2003 •Spun off into a separate entity - Glenmark Laboratories Ltd.


    •Changed its name to "Marksans Pharma Ltd

    •Acquired Nova Pharmaceuticals Australasia Pty Ltd. by 60%


    2005 of stake.

    •Acquired Bells, Sons & Co. (Druggists) Ltd.


    2007 •Acquired Relonchem Limited

    •Marksans Pharma established itself as a global player


    2008
    •Acquired Time Cap Laboratories Inc. USA
    2015
    •Acquired Access Healthcare Dubai by 100% of stake.
    2022
    •Acquired a manufacturing facility from Tevapharm India.
    2023
    PRODUCT PORTFOLIO:

    DEALS TWO MAJOR PRDUCTS:

    1.OTC(Pain Management, Cough and Cold, Gastrointestinal, Vitamin & supplements, Anti-Allergic)

    2.PRESCRIPTION DRUGS(– CVS, CNS and Anti-Diabetic)

    In the above products which company manufactures pain management drugs are at
    highest selling and revenue generated product followed by cough and cold

    YEARLY REVENUE:

    REVENUE

    PESCRIPTION DRUGS 31.40%

    OTC 68.60%

    MARKET OF MARKSANS PHARMA:

    1. USA:
     Manufactures, tablets and capsules.
     This facility offers a diverse range of products across Private Label OTC, Generic Prescription
    Drugs, and Nutritional Supplements, including Gastrointestinal, Laxatives, Pain
    Management, Analgesics, Cold and Cough, and Anti-Allergy
     Marksans is the first Indian company with US-FDA approval for Claritin soft gel capsules
    (Loratadine).
     OTC products are manufactured by TCL in the USA, while ANDA-approved products are
    manufactured at the Goa facility and exported to North American countries.
    2. UK AND EUROPE:
     Since 2007, Marksans has been actively serving the UK market, establishing itself as one of
    the top Indian companies in the region.
     Marksans Pharma UK Ltd., along with our two step-down subsidiaries, Bell, Sons & Co.
    (Druggists) Limited and Relonchem, both acquired in 2008.
     Bells Healthcare specializes in delivering high-quality own-label products across various
    therapeutic areas like analgesics, cough and cold, pain relief, gastrointestinal, ear care, and
    skin care.
     Relonchem, on the other hand, offers an extensive range of own-label healthcare
    pharmaceutical products covering areas such as anti-diabetic, antihypertensive,
    antidepressant, anti-cancer, anti-ulcerative, allergy relief, anti-viral, and pain relief in the UK
    market.
     Manufactures non-sterile liquids, ointments and powder sachets.

    3. AUSTRALIA:
     Presence in Australia and New Zealand through subsidiary Nova Pharmaceuticals in 2005.
     Nova is engaged in the R&D and marketing of generic OTC products, with a focus on
    analgesics, antihistamines, anti-fungal, anti-allergy, dermatology, essential oils, and
    gastrointestinal segments. All Nova products comply with TGA Australia regulations .

    4. ROW :
     Presence in Middle East, Southeast Asia, CIS, Russia and Africa.
     Company has acquired AHC in UAE that will strengthen its presence in MENA region

    REVENUE=715.3
    USA UK AND EUROPE AUSTRALIA ROW

    6%
    11%

    41%

    42%
    FINANCIAL ANALYSIS:

    ANNUAL RESULTS:

    Indicator Mar '23 Mar '22 Mar '21 Mar '20


    Total Revenue 1,911.5 1,532.7 1,382.9 1,134.5
    Operating 1,512.8 1,232 1,036.6 942
    Expenses
    Operating Profit 339.3 258.9 339.6 192.3
    Operating Profit 17.75% 16.89% 24.56% 16.95%
    Margin %
    Total Expenses 1,573.8 1,285.2 1,080.7 977.4
    EBIDT 398.6 300.7 346.3 192.6
    EBIDT margin % 20.86% 19.62% 25.04% 16.97%
    Interest 9.1 8.4 8 8.7
    Depreciation 51.9 44.8 36.2 26.7
    Profit Before Tax 337.7 247.5 302.2 157.2
    Tax 72.3 60.7 63.6 36.4
    PAT Before 265.3 186.8 238.5 120.8
    ExtraOrdinary
    Items
    Net Profit 266.3 186.8 238.5 120.8
    Net Profit Margin 14.32% 12.53% 17.33% 10.64%
    %
    EPS 6.4 4.5 5.8 2.9

     Annual Net Profit is Rs 266 Cr which is growth of 42.6% YoY.


     Company has delivered good profit growth of 51.8% CAGR over last 5 years
     Emense high was seen in PBT of by the year 23 of 36.43%.
     Revenue growth will be further supported by continuing product diversification given a larger
    product base and geographical expansion.
     The earnings before interest, tax, depreciation and amortisation (EBITDA) margin during the first
    nine months of fiscal 2024 was healthy at 32.6% (~32.6% in the corresponding period of the
    previous fiscal) driven by stable gross margin
     EPS has shown a rise from 4.5 to 6.4.
     Total revenue has grown from 1532 to 1911.
    BALANCE SHEET ANALYSIS:

    Indicator Mar '23 Mar '22 Mar '21 Mar '20 M


    Total ShareHolders 1,745.2 1,202.3 886.5 636
    Funds
    Minority Interest 19.9 20.7 18.9 13.1
    Liability
    Total Non Current 84.3 60.9 24.5 24.8
    Liabilities
    Total Current 341 356.2 298.4 228.8
    Liabilities
    Total Capital Plus 2,190.4 1,640.1 1,228.3 902.7
    Liabilities
    Fixed Assets 457.7 400.9 321 302.7
    Total Non Current 515.1 438.9 326 309.1
    Assets
    Total Current Assets 1,675.3 1,201.2 902.3 593.6
    Total Assets 2,190.4 1,640.1 1,228.3 902.7
    Contingent Liabilities 9.3 17 19.8 48.2
    plus Commitments

     Shareholder funds are growing at stable speed and at current they valued at Rs.1745cr.which is
    agrowth of 45.2% YoY.
     Total Assets is Rs 2,190 Cr which is growth of 33.6% YoY.

    CASH FLOW ANALYSIS:

    Indicator Graph CAGR 3 Yrs CAGR 5 Yrs Mar '23


    Cash from Operating 4.2% 36.5% 237.4
    Activity
    Cash from Investing -63.3% -46.2% -259.2
    Activity
    Cash from Financing 319.5% 125.4% 197.8
    Activity
    Net Cash Flow 42.9% 64.3% 176

     Cash From Operating Activity is Rs 237 Cr which is growth of 139.2% YoY.


     Net Cash Flow is Rs 176 Cr which is growth of 28.4% YoY.
     Healthy Free Cash Flow of ₹65.0 cr. in H1FY23
    CURRENT VALUATION:

     Company has delivered good profit growth of 51.8% CAGR over last 5 years
     Company is almost debt free.
     Current share price of the company marksans stood at Rs. 161
     Current P/E ratio is calcylated about 23.0
     ROE declining in the last 2 years and in FY23 is stood about 18.6%

    COMPANY’S OUTLOOK:

     Expanding in other geographies by acquiring companies with the same strategy of distribution of OTC
    Products through store brands Expanding in other geographies by acquiring companies with Rx capabilities
    Expanding to have significant international footprint
     EBITDA Margin expected >25% driven by full integration for key formulations
     Aim is to rank amongst Top 10 Indian Pharma companies in US and Top 3 Indian Pharma Companies in the
    UK
     OTC mix expected to increase to >70%
     Generate 10% of the revenue from Rest of World (RoW)
     Increasing presence in EU •
     Adding new delivery systems
     Expanding across geographies
     Backward Integration •
     100% coverage- across strategic therapeutic segments

    REFERENCE:

    TRENDLYNE

    SHARESCART

    MARKSANS PHARMA ANNUAL REPORT

    ICICI REPORT

    SCREENER

    You might also like